Stefania Capone

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.

Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates.

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.

Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.

Antibody response to respiratory syncytial virus infection in children <18 months old.

Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.

Induction and Maintenance of CX3CR1-Intermediate Peripheral Memory CD8 T Cells by Persistent Viruses and Vaccines.

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal.

Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.

Characterizing Hepatitis C Virus-Specific CD4 T Cells Following Viral-Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure.

A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.

Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans.

Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys.